-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows

Benzinga·09/14/2026 05:46:12
Listen to the news
  • Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab
  • HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months
  • PD-L1 High Expression Subgroup: Hazard Ratio = 0.58
  • Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC